Wolfe said the oral GLP-1 therapy could broaden the obesity treatment market because it combines strong weight-loss results with the convenience of a pill. The firm compared the potential launch to ...

Financial support to prepare the submission of the Phase 2 clinical trial application for NFL-102 expected in mid-2026 Strengthening ...

For the more than 48 million Americans with substance use disorders, including a disproportionate share of veterans, GLP-1 drugs are not yet an approved addiction treatment. But the evidence base is ...